Gene Therapy for Pancreatic Cancer: Specificity, Issues and Hopes

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Pancreatic ductal adenocarcinoma is projected to be the second leading cause of cancer death by 2030, with a very poor prognosis.
• There is an urgent need for novel therapeutic strategies beyond conventional chemotherapy to improve outcomes for pancreatic cancer patients.

Purpose of the Study:

• To provide an overview of gene therapy strategies for pancreatic cancer.
• To review experimental models, vectors, molecular tools, and therapeutic genes used in pancreatic cancer gene therapy.
• To describe recent advancements, including oncolytic virus therapies and clinical trial updates.

Main Methods:

• Review of current literature on pancreatic cancer gene therapy.
• Analysis of experimental in vivo models, expression vectors, and molecular tools.
• Summary of therapeutic gene types: tumor suppressor, antiangiogenic, pro-apoptotic, and suicide genes.
• Description of gene-based sensitization to chemotherapy, vaccination, and adoptive immunotherapy (CAR T-cells).
• Overview of oncolytic virus therapies (adenoviruses, herpes virus, parvovirus, reovirus).
• Summary of published and ongoing Phase 1 clinical trials, often combining gene therapy with chemotherapy or radiochemotherapy.

Main Results:

• Gene therapy presents a promising approach for pancreatic cancer treatment.
• Latest developments include gene-based sensitization, immunotherapy, and oncolytic virus therapies.
• Phase 1 clinical trials combining gene therapy with conventional treatments show encouraging initial results.

Conclusions:

• Gene therapy, particularly with oncolytic viruses and combined treatment modalities, offers a hopeful new direction for pancreatic cancer therapeutics.
• While early clinical trial results are encouraging, further validation in Phase 2 trials is necessary.